Advertisement

PharmacoEconomics

, Volume 32, Issue 12, pp 1201–1212 | Cite as

A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments

  • Andrew Messali
  • Reginald Villacorta
  • Joel W. HayEmail author
Review Article

Abstract

Grade IV glioma (glioblastoma) is one of the most common brain/central nervous system cancers. In 2005, the standard of care for adjuvant treatment was significantly changed with the approval of temozolomide. Carmustine wafers have also gained some popularity. Phase III trials are currently evaluating bevacizumab in conjunction with the standard temozolomide regimen. Despite these recent advances in pharmacotherapy, roughly two-thirds of patients do not survive longer than 2 years after diagnosis. Meanwhile, the costs of treatment are substantial. The goal of this study is to review the clinical, cost-of-illness, and cost-effectiveness literature relevant to treating glioblastoma. Estimates of the economic burden of glioblastoma within different healthcare systems were converted to 2013 US dollars. Temozolomide has demonstrated a 2.5-month increase in overall survival and a 1.9-month increase in progression-free survival, relative to radiotherapy alone. Carmustine wafers have also been shown to increase overall survival by 2.3 months, compared with placebo wafers. Cost-effectiveness studies of temozolomide have produced incremental cost-effectiveness ratios, adjusted to 2013 US dollars, with a range from US$73,586 per quality-adjusted life-year (QALY) (UK National Health Service perspective) to US$105,234 per QALY (US societal perspective). More research is needed to quantify the full societal burden of illness.

Keywords

Overall Survival Bevacizumab Temozolomide Probabilistic Sensitivity Analysis Glioblastoma Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Statement on financial disclosure/conflict of interest

Dr. Messali, Mr. Villacorta, and Dr. Hay have no conflicts of interest to declare.

Author contributions

Dr. Andrew Messali, Mr. Reginald Villacorta, and Dr. Joel Hay had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Messali, Villacorta, Hay. Acquisition of data: Messali, Villacorta. Analysis and interpretation of data: Messali, Villacorta, Hay. Drafting of the manuscript: Messali, Villacorta, Hay. Critical revision of the manuscript for important intellectual content: Messali, Villacorta, Hay. Final guarantor of content: Messali.

References

  1. 1.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012;14(Suppl 5):v1–49.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79–88.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for maligannt glioma: long-term folow-up of a multicenter controlled trial. Acta Neurochir. 2006;148:269–75.PubMedCrossRefGoogle Scholar
  5. 5.
    Stupp R, Mason WP, van den Bent MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRefGoogle Scholar
  6. 6.
    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomsed phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.PubMedCrossRefGoogle Scholar
  7. 7.
    Gilbert MR, Dignam J, Won M. RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol. 2013;31(18 Suppl 1):1.Google Scholar
  8. 8.
    Chinot O. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglio. 17th Annual Meeting of the Society for Neuro Oncology. 2012 Nov 17; Plenary Session5 (Abstract OT-03).Google Scholar
  9. 9.
    Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas. J Am Med Assoc. 2013;310(17):1842–50.CrossRefGoogle Scholar
  10. 10.
    de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63(3):535–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Tailibert S, Lieberman F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smreka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192–202.PubMedCrossRefGoogle Scholar
  12. 12.
    Messali A, Hay J, Villacorta R. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol. 2013;15(11):1532–42.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Consumer price index estimated from the United States Bureau of Labor Statistics. 04 Jan 2014; Available from: http://www.bls.gov/data/inflation_calculator.htm.
  14. 14.
    Purchasing power parity estimated from the Organization for Economic Cooperation and Development. 04 Jan 2014; Available from: http://stats.oecd.org/Index.aspx?datasetcode=SNA_TABLE4.
  15. 15.
    Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Henriksson R. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916–26.PubMedCrossRefGoogle Scholar
  16. 16.
    Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blashcke B, Meyermann R, Reifenberger G, Weller M, Wick W. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patient with recurrent glioma. J Clin Oncol. 2007;25(22):3357–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28(12):2051–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Omuro A, Chan TA, Abrey LE, Kharsaw M, Reiner AS, Kaley TJ, DeAngelis LM, Lassman AB, Nolan CP, Gavriloc IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol. 2013;12(2):242–50.CrossRefGoogle Scholar
  19. 19.
    Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent glimas. Lancet. 1995;345:1008–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Latif AZ, Signorini D, Gregor A, Wittle IR. The costs of managing patients with malignant glioma at a neuro-oncology clinc. Br J Neurosurg. 1998;12:118–22.PubMedCrossRefGoogle Scholar
  22. 22.
    Mendez I, Jacobs P, MacDougall A, Schultz M. Treatment costs for glioblastoma multiforme in Nova Scotia. Can J Neurol Sci. 2001;28:61–5.PubMedGoogle Scholar
  23. 23.
    Blomqvist P, Lycke J, Strang P, Tornqvist H, Ekbom A. Brain tumors in Sweden 1996: care and costs. J Neurol Neurosurg Psychiatry. 2000;69:792–8.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Wasserfallen JB, Ostermann S, Pica A, Mirimanoff RO, Leyvraz S, Villemur JG. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer. 2004;101:2098–105.PubMedCrossRefGoogle Scholar
  25. 25.
    Hamilton D. Evidence, economics, and emotions: the case for temozolomide. N Z Med J. 2005;118(1227):1–5.Google Scholar
  26. 26.
    Martikainen JA, Kivioja A, Hallinen T, Vihinen P. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. Pharmacoeconomics. 2005;23(8):803–15.PubMedCrossRefGoogle Scholar
  27. 27.
    Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):1–258.Google Scholar
  28. 28.
    Wu B, Miao Y, Bai Y, Ye M, Xu Y, Chen H. Subgroup economic analysis for glioblastoma in a health resource-limited setting. PLoS One. 2012;7(4):e34588.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Lamers LM, Stupp R, van den Ben MJ, Al MJ, Gorlia T, Wasserfallen JB. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Cancer. 2008;112:1337–44.PubMedCrossRefGoogle Scholar
  30. 30.
    Central nervous system cancers, version 2. 2013. NCCN clinical practice guidelines in oncologyGoogle Scholar
  31. 31.
    Group GM-aTG. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011–8.CrossRefGoogle Scholar
  32. 32.
    Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009;11(1):69–79.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Andrew Messali
    • 1
  • Reginald Villacorta
    • 1
  • Joel W. Hay
    • 1
    Email author
  1. 1.Department of Clinical Pharmacy and Pharmaceutical Economics and PolicyLeonard D. Schaeffer Center for Health Policy and Economics, University of Southern CaliforniaLos AngelesUSA

Personalised recommendations